Antiretroviral activity of didanosine in patients with different clusters of reverse transcriptase mutations

AIDS. 2006 Sep 11;20(14):1891-2. doi: 10.1097/01.aids.0000244210.33876.26.

Abstract

Patterns of mutations associated with didanosine (ddI) resistance are still a controversial issue. The correlation between different clusters of reverse transcriptase mutations with the short-term virological activity of ddI when added to a failing regimen was examined in 40 patients. The median fall in plasma viral load at week 4 was 0.67 log10 copies/ml. There was good correlation between the median fall in plasma HIV RNA levels and the number of nucleoside-associated (P = 0.0152) or thymidine-associated (P = 0.0142) mutations. In conclusion, ddI retained substantial antiretroviral activity when the number of nucleoside-associated or thymidine-associated mutations was less than four.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Didanosine / therapeutic use*
  • HIV Infections / drug therapy*
  • HIV Infections / genetics
  • HIV Reverse Transcriptase / genetics
  • Humans
  • Mutation
  • Nucleosides / genetics
  • Prospective Studies
  • RNA, Viral / analysis
  • Reverse Transcriptase Inhibitors / therapeutic use*
  • Thymidine / genetics
  • Treatment Outcome
  • Viral Load

Substances

  • Nucleosides
  • RNA, Viral
  • Reverse Transcriptase Inhibitors
  • HIV Reverse Transcriptase
  • Didanosine
  • Thymidine